This is the first in human study of MOR107. It is a 2 part, single centre, double-blind, randomised, placebo-controlled study in healthy male subjects. Part 1 is a single ascending dose study, and Part 2 is a parallel group, dose range finding study in healthy male subjects on a low sodium diet.
MOR107 is an angiotensin 2 receptor (AT2R) agonist with the potential to treat a wide range of diseases through activation of the protective arm of the renin-angiotensin system. In this study MOR107 will be administered to humans for the first time. The study will enroll healthy male subjects and is split into two sequential parts, both of which have a single centre, double-blind, randomised, placebo-controlled design. Part 1 will evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending doses of MOR107. Part 2 will evaluate the pharmacodynamics, safety, tolerability and PK of three different doses of MOR107 in healthy male subjects who will be fed a low sodium diet in order to increase AT2R expression.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
24
MOR107 solution for injection
Solution for injection manufactured to match MOR107 solution for injection
Diet designed to restrict sodium intake to 40 mmol/day
Quotient Clinical
Nottingham, Nottinghamshire, United Kingdom
Incidence of treatment-emergent adverse events (safety and tolerability)
Reporting of adverse events, physical examination, injection site assessment, vital signs, ECG, and clinical chemistry, haematology and urinalysis
Time frame: Up to 10 days post-dose
Time from dosing at which the maximum MOR107 concentration was observed (Tmax)
Plasma PK parameter
Time frame: Up to 48 hours post-dose
Maximum observed MOR107 concentration (Cmax)
Plasma PK parameter
Time frame: Up to 48 hours post-dose
Concentration of MOR107 at 12 hours post-dose (C12)
Plasma PK parameter
Time frame: 12 hours post-dose
Concentration of MOR107 at 24 hours post-dose (C24)
Plasma PK parameter
Time frame: 24 hours post-dose
Area under the curve from 0 time to last measurable MOR107 concentration (AUC0-t)
Plasma PK parameter
Time frame: Up to 48 hours post-dose
Area under the curve from 0 time to infinity for MOR107 (AUC0-inf)
Plasma PK parameter
Time frame: Up to 48 hours post-dose
Percentage of AUC(0-inf) for MOR107 extrapolated beyond last measured time point (AUC%extrap)
Plasma PK parameter
Time frame: Up to 48 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Slope of the apparent elimination phase for MOR107 (Lambda-z)
Plasma PK parameter
Time frame: Up to 48 hours post-dose
Apparent elimination half-life for MOR107 (T-half)
Plasma PK parameter
Time frame: Up 48 hours post-dose
MOR107 Cmax normalised for dose (Cmax/D)
Plasma PK parameter
Time frame: Up to 48 hours post-dose
MOR107 AUC(0-t) normalised for dose (AUC[0-t]/D)
Plasma PK parameter
Time frame: Up to 48 hours post-dose
MOR107 AUC(0-inf) normalised for dose (AUC[0-inf]/D)
Plasma PK parameter
Time frame: Up to 48 hours post-dose
Amount of MOR107 excreted in the urine over a specified period of time after dosing (Ae)
Urine PK parameter
Time frame: Up to 48 hours post-dose
Cumulative amount of MOR107 excreted in the urine (CumAe)
Urine PK parameter
Time frame: Up to 48 hours post-dose
Amount of MOR107 excreted in the urine over a specified period of time after dosing, expressed as a percentage of the administered dose (Ae%)
Urine PK parameter
Time frame: Up to 48 hours post-dose
Cumulative amount of MOR107 excreted in the urine, expressed as a percentage of the administered dose (CumAe%)
Urine PK parameter
Time frame: Up to 48 hours post-dose
Renal clearance: the apparent volume of plasma cleared per unit time via renal elimination (CLr)
Urine PK parameter
Time frame: Up to 48 hours post-dose